title: Mortality Similar for Prostate Cancer Therapies.
abstract: The UK-based ProtecT trial reports that, after a median of 10 years of follow up, there is no significant difference in prostate cancer-specific mortality between active monitoring, surgery, and radiotherapy. However, the likelihood of developing metastases is more than twice as great with active monitoring compared with treatment.
mesh_terms: D000368:Aged; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D007610:Kallikreins / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D011468:Prostatectomy / Q000401:mortality*; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D011788:Quality of Life; D011878:Radiotherapy / Q000401:mortality*; D057832:Watchful Waiting
chemical_list: C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen